Literature DB >> 22826109

Human mesenchymal stem cells increase anti-oxidant defences in cells derived from patients with Friedreich's ataxia.

Rimi Dey1, Kevin Kemp, Elizabeth Gray, Claire Rice, Neil Scolding, Alastair Wilkins.   

Abstract

Friedreich's ataxia (FRDA) is a progressive neurodegenerative disorder which is, at present, incurable. Oxidative damage and inhibition of mitochondrial function are key determinants of cellular damage in FRDA, since there is greater sensitivity to oxidative stress in cells with frataxin deficiency. In addition, frataxin-deficient cells have an impaired ability to recruit antioxidant defences against endogenous oxidative stress. We have recently shown that factors derived from bone marrow-derived mesenchymal stem cells (MSCs) increase hydrogen peroxide scavenging enzymes and offer protection against hydrogen peroxide-mediated injury in cells derived from patients with FRDA. Here we extend these studies and have performed a series of experiments showing that expression of superoxide dismutase (1 and 2) enzymes is reduced in FRDA cells but can be restored by treatment with conditioned medium from human MSCs. Furthermore, we have demonstrated that exposure to factors secreted by MSCs increases resistance to nitric oxide-induced oxidative stress in FRDA fibroblasts through, at least in part, restoring the expression of the superoxide dismuting enzymes and via modulation of PI(3) kinase/Akt pathways. These findings suggest that MSCs secrete factors that improve the cellular homeostasis of cells derived from FRDA patients and provide suitable support for their enhanced survival. This study further suggests the potential therapeutic use of MSCs in patients with FRDA.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22826109     DOI: 10.1007/s12311-012-0406-2

Source DB:  PubMed          Journal:  Cerebellum        ISSN: 1473-4222            Impact factor:   3.847


  56 in total

1.  Deletion of the yeast homologue of the human gene associated with Friedreich's ataxia elicits iron accumulation in mitochondria.

Authors:  F Foury; O Cazzalini
Journal:  FEBS Lett       Date:  1997-07-14       Impact factor: 4.124

Review 2.  Friedreich's ataxia: pathology, pathogenesis, and molecular genetics.

Authors:  Arnulf H Koeppen
Journal:  J Neurol Sci       Date:  2011-04-15       Impact factor: 3.181

3.  Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia.

Authors:  David Herman; Kai Jenssen; Ryan Burnett; Elisabetta Soragni; Susan L Perlman; Joel M Gottesfeld
Journal:  Nat Chem Biol       Date:  2006-08-20       Impact factor: 15.040

4.  Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide.

Authors:  J S Beckman; T W Beckman; J Chen; P A Marshall; B A Freeman
Journal:  Proc Natl Acad Sci U S A       Date:  1990-02       Impact factor: 11.205

5.  Frataxin deficiency and mitochondrial dysfunction.

Authors:  Massimo Pandolfo
Journal:  Mitochondrion       Date:  2002-11       Impact factor: 4.160

Review 6.  Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich's ataxia.

Authors:  Vittorio Calabrese; Raffaele Lodi; Caterina Tonon; Velia D'Agata; Maria Sapienza; Giovanni Scapagnini; Andrea Mangiameli; Giovanni Pennisi; A M Giuffrida Stella; D Allan Butterfield
Journal:  J Neurol Sci       Date:  2005-06-15       Impact factor: 3.181

Review 7.  Friedreich's ataxia: treatment within reach.

Authors:  Alexandra Dürr
Journal:  Lancet Neurol       Date:  2002-10       Impact factor: 44.182

Review 8.  Friedreich ataxia: the clinical picture.

Authors:  Massimo Pandolfo
Journal:  J Neurol       Date:  2009-03       Impact factor: 4.849

9.  Real time PCR quantification of frataxin mRNA in the peripheral blood leucocytes of Friedreich ataxia patients and carriers.

Authors:  L Pianese; M Turano; M S Lo Casale; I De Biase; M Giacchetti; A Monticelli; C Criscuolo; A Filla; S Cocozza
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-07       Impact factor: 10.154

10.  Impaired nuclear Nrf2 translocation undermines the oxidative stress response in Friedreich ataxia.

Authors:  Vincent Paupe; Emmanuel P Dassa; Sergio Goncalves; Françoise Auchère; Maria Lönn; Arne Holmgren; Pierre Rustin
Journal:  PLoS One       Date:  2009-01-22       Impact factor: 3.240

View more
  12 in total

1.  Pericytes Extend Survival of ALS SOD1 Mice and Induce the Expression of Antioxidant Enzymes in the Murine Model and in IPSCs Derived Neuronal Cells from an ALS Patient.

Authors:  Giuliana Castello Coatti; Miriam Frangini; Marcos C Valadares; Juliana Plat Gomes; Natalia O Lima; Natale Cavaçana; Amanda F Assoni; Mayra V Pelatti; Alexander Birbrair; Antonio Carlos Pedroso de Lima; Julio M Singer; Francisco Marcelo M Rocha; Giovani Loiola Da Silva; Mario Sergio Mantovani; Lucia Inês Macedo-Souza; Merari F R Ferrari; Mayana Zatz
Journal:  Stem Cell Rev Rep       Date:  2017-10       Impact factor: 5.739

2.  The Favorable Effect of Mesenchymal Stem Cell Treatment on the Antioxidant Protective Mechanism in the Corneal Epithelium and Renewal of Corneal Optical Properties Changed after Alkali Burns.

Authors:  Cestmir Cejka; Vladimir Holan; Peter Trosan; Alena Zajicova; Eliska Javorkova; Jitka Cejkova
Journal:  Oxid Med Cell Longev       Date:  2016-01-05       Impact factor: 6.543

3.  Mesenchymal Stem Cell-Derived Factors Restore Function to Human Frataxin-Deficient Cells.

Authors:  Kevin Kemp; Rimi Dey; Amelia Cook; Neil Scolding; Alastair Wilkins
Journal:  Cerebellum       Date:  2017-08       Impact factor: 3.847

4.  Reduced aldehyde dehydrogenase expression in preeclamptic decidual mesenchymal stem/stromal cells is restored by aldehyde dehydrogenase agonists.

Authors:  Gina D Kusuma; Mohamed H Abumaree; Anthony V Perkins; Shaun P Brennecke; Bill Kalionis
Journal:  Sci Rep       Date:  2017-02-13       Impact factor: 4.379

Review 5.  Mesenchymal stem cells to treat liver diseases.

Authors:  Young Woo Eom; Seong Hee Kang; Moon Young Kim; Jong In Lee; Soon Koo Baik
Journal:  Ann Transl Med       Date:  2020-04

6.  The Effect of Human Umbilical Cord Mesenchymal Stromal Cells in Protection of Dopaminergic Neurons from Apoptosis by Reducing Oxidative Stress in the Early Stage of a 6-OHDA-Induced Parkinson's Disease Model.

Authors:  Heng Chi; Yunqian Guan; Fengyan Li; Zhiguo Chen
Journal:  Cell Transplant       Date:  2019-11-28       Impact factor: 4.064

7.  Extracellular vesicles derived from human Wharton's jelly mesenchymal stem cells protect hippocampal neurons from oxidative stress and synapse damage induced by amyloid-β oligomers.

Authors:  Victor Bodart-Santos; Luiza R P de Carvalho; Mariana A de Godoy; André F Batista; Leonardo M Saraiva; Luize G Lima; Carla Andreia Abreu; Fernanda G De Felice; Antonio Galina; Rosalia Mendez-Otero; Sergio T Ferreira
Journal:  Stem Cell Res Ther       Date:  2019-11-20       Impact factor: 6.832

Review 8.  Hyperoxia-induced bronchopulmonary dysplasia: better models for better therapies.

Authors:  Kiersten Giusto; Heather Wanczyk; Todd Jensen; Christine Finck
Journal:  Dis Model Mech       Date:  2021-02-23       Impact factor: 5.758

9.  Reduced neuroprotective potential of the mesenchymal stromal cell secretome with ex vivo expansion, age and progressive multiple sclerosis.

Authors:  Pamela Sarkar; Juliana Redondo; Kevin Kemp; Mark Ginty; Alastair Wilkins; Neil J Scolding; Claire M Rice
Journal:  Cytotherapy       Date:  2017-09-13       Impact factor: 5.414

10.  Secretome released from hydrogel-embedded adipose mesenchymal stem cells protects against the Parkinson's disease related toxin 6-hydroxydopamine.

Authors:  Armando Chierchia; Nino Chirico; Lucia Boeri; Ilaria Raimondi; Giovanni A Riva; Manuela Teresa Raimondi; Marta Tunesi; Carmen Giordano; Gianluigi Forloni; Diego Albani
Journal:  Eur J Pharm Biopharm       Date:  2017-09-28       Impact factor: 5.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.